Phase 3 outcomes are not yet published
Medical history, current medications, diabetes status, heart health, kidney health, stomach problems, insurance coverage, and weight goals all matter
Primary effects: All GLP-1 effects plus enhanced insulin secretion, possible direct effects on fat metabolism, potentially reduced nausea through GIP-mediated pathways
For MASLD this has mainly focused on liver-related outcomes, although the potential impact on other related diseases ( e.g., cardiovascular disease, extrahepatic malignancy) and quality of life are increasingly being explored (including in interventional trials) as part of a more holistic approach
Encyclopedia of Signaling Molecules
Whether your stomach is full or empty when you inject has no effect on how the medication is absorbed